je.st
news
Tag: forecasts
Research Analysts Issue Forecasts for Shenandoah Telecommunications...
2016-02-08 11:40:47| Telecom - Topix.net
Shenandoah Telecommunications Company - Investment analysts at BWS Financial issued their FY2015 earnings per share estimates for Shenandoah Telecommunications Company in a research note issued on Thursday, Zacks Investment Research reports. BWS Financial analyst H. Khorsand forecasts that the brokerage will post earnings per share of $0.80 for the year.
Tags: research
issue
telecommunications
analysts
Equities Analysts Issue Forecasts for Air Products & Chemicals,...
2016-02-06 19:59:29| Chemicals - Topix.net
Air Products & Chemicals, Inc. - Equities research analysts at Seaport Global Securities upped their Q1 2016 earnings per share estimates for shares of Air Products & Chemicals in a report released on Tuesday, Zacks Investment Research reports. Seaport Global Securities analyst M. Harrison now expects that the firm will post earnings of $1.79 per share for the quarter, up from their prior forecast of $1.76.
Tags: products
air
issue
chemicals
Genesco Inc. (GCO) to Post FY2016 Earnings of $4.35 Per Share, BB&T Corp. Forecasts
2016-02-05 13:06:42| Footwear - Topix.net
BB&T Corp. issued their FY2016 earnings per share estimates for shares of Genesco in a note issued to investors on Tuesday, according to Zacks Investment Research . BB&T Corp. analyst S. Krasik anticipates that the brokerage will post earnings of $4.35 per share for the year.
Tags: post
share
corp
earnings
IDTechEx forecasts more than 300M 48V mild hybrids worldwide through 2031
2016-02-03 11:55:40| Green Car Congress
Tags: through
worldwide
mild
forecasts
Gilead Sciences beats 4th-quarter forecasts on higher sales
2016-02-03 10:33:31| Biotech - Topix.net
Gilead Sciences Inc. posted a 34 per cent increase in fourth-quarter profit, trouncing Wall Street expectations, as sales of its blockbuster hepatitis C drugs soared in Japan and offset lower sales in the U.S. The maker of Harvoni, the first once-daily, single-pill regimen for hepatitis C, and predecessor drug Sovaldi, has been propelled by the lucrative franchise since Sovaldi was launched at the end of 2013. They're the main reason the company's revenue has tripled in just two years, a rare accomplishment in the industry.
Tags: sales
higher
sciences
beats
Sites : [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] next »